

SPEAKER BIOSKETCH

NAME, SURNAME: Cansu, Tekin

TITLE: Unlocking Translational Potential Through EATRIS Mentoring

ORCID ID: 0000-0003-3961-5603

CURRENT AND PAST POSITIONS:

- *Innovation Manager*, EATRIS (May 2025–Present)
Leading innovation strategy, stakeholder collaboration, and translational research support across Europe.
- *Product Manager*, Bess AG (Mar 2024–Apr 2025)
Developed global launch strategies for novel medical devices; led cross-functional teams and training.
- *Project Head*, iGEM Community (January 2023–December 2023)
Led global teams on biotech education and entrepreneurship; organized workshops and publications.
- *Technology Analyst and Innovation Manager*, Insempra GmbH (July 2021–April 2023)
Scouted biotechnologies, secured funding, managed partnerships, and delivered strategic insights.

EDUCATION:

Ph.D., Experimental & Molecular Oncology – Univ. of Amsterdam (2015–2021)

M.Sc., Biomedical Sciences – Univ. of Amsterdam (2013–2015)

B.Sc., Molecular Biology & Genetics – Bilkent University (2009–2013)

OTHER RELEVANT PROFESSIONAL ACTIVITIES AND ACCOMPLISHMENTS:

Mentor (iGEM VCL, 2022–23), Judge (iGEM Jamboree, 2022)

Skilled in innovation strategy, grant writing, product management, and stakeholder engagement

PRESENTATION OUTLINE AND ABOUT EATRIS:

EATRIS, the European infrastructure for translational medicine, helps researchers navigate the complex journey from discovery to patient impact. Its mentoring program provides tailored, hands-on support in key areas such as product classification, biomarker validation strategies, regulatory and early technology assessment guidance, manufacturing considerations, and translational strategy. The aim is to help researchers identify and solve critical obstacles early, ensuring the best chance of success towards future funding, partnerships, and future clinical adoption. As an ERIC (European Research Infrastructure Consortium), EATRIS unites over 150 top-tier academic centers across Europe, providing access to cutting-edge preclinical and clinical expertise to accelerate the development of diagnostics, drugs, vaccines, and advanced therapies.